Is GLP-2 the same as GLP-1?

No. They come from the same precursor protein and are released together, but they bind different receptors and do different jobs. GLP-1 affects insulin secretion, gastric emptying and appetite; GLP-2 grows and repairs the intestinal lining.

Does GLP-2 cause weight loss?

No. Its documented effect is to increase intestinal absorptive capacity, which is the opposite direction of travel from an obesity treatment. GLP-2 analogues are approved for short bowel syndrome, not weight management.

No. There is no GLP-3 hormone or receptor. The term circulates online as a nickname for retatrutide, an investigational triple agonist of the GLP-1, GIP and glucagon receptors.

Why does GLP-2 need to be injected?

It is a peptide, so swallowing it exposes it to digestive proteases that would destroy it before absorption. Approved GLP-2 analogues are given subcutaneously.

What is teduglutide used for?

It is a DPP-4-resistant GLP-2 analogue approved for short bowel syndrome, where it increases absorption from the remaining intestine and reduces dependence on parenteral nutrition. It is used under specialist supervision with periodic colonoscopic monitoring.

GLP-2: the intestinal sibling of GLP-1

Cleaved from the same proglucagon precursor as GLP-1, GLP-2 acts on an entirely different receptor and does an entirely different job: it grows, repairs and increases the absorptive capacity of the intestinal lining.

UPDATED 09 SEPT 2026 · 9 MIN READ

KEY TAKEAWAYS

GLP-2 and GLP-1 are cut from the same precursor protein, proglucagon, but bind separate receptors and produce unrelated effects.
The GLP-2 receptor is expressed on intestinal subepithelial cells, enteric neurons and enteroendocrine cells rather than on the absorptive enterocytes themselves, so the growth signal is relayed indirectly.
GLP-2 increases villus height, crypt depth, mucosal blood flow and barrier integrity — it is a trophic hormone for the gut, not a metabolic one.
Native GLP-2 is degraded by DPP-4 within minutes; teduglutide is a DPP-4-resistant analogue approved for short bowel syndrome.
GLP-2 analogues are not weight-loss drugs. Their purpose is to increase intestinal absorption, which is the opposite of what an obesity treatment is trying to achieve.
Because GLP-2 promotes growth of intestinal tissue, labelling for approved analogues carries warnings about neoplastic growth and requires colonoscopic surveillance.

What GLP-2 is

Glucagon-like peptide-2 is a 33-amino-acid hormone released by intestinal L-cells — the same cells that release GLP-1, and in response to the same stimulus: nutrients arriving in the gut lumen. Both peptides are carved out of proglucagon, a single precursor protein that is processed differently depending on the tissue. In the pancreatic alpha cell, proglucagon yields glucagon. In the intestinal L-cell, prohormone convertase 1/3 cuts it into GLP-1, GLP-2 and several other fragments.

That shared origin is the reason for the confusing family name. It does not imply shared function. GLP-1 and GLP-2 are co-secreted in roughly equal amounts after a meal and then go their separate ways: GLP-1 to the pancreas, stomach and brain, GLP-2 to the intestinal wall immediately around the cells that released it.

The GLP-2 receptor

The GLP-2 receptor is a class B G-protein-coupled receptor, structurally related to the GLP-1 and glucagon receptors but pharmacologically distinct. GLP-1 does not meaningfully activate it, and GLP-2 does not meaningfully activate the GLP-1 receptor. This is why a GLP-1 agonist does not produce intestinal growth and why a GLP-2 analogue does not lower blood glucose or suppress appetite.

Its distribution is narrow and mostly confined to the gastrointestinal tract. Notably, the receptor is not found in quantity on the enterocytes — the absorptive cells that actually enlarge in response to GLP-2. Instead it sits on subepithelial myofibroblasts, enteric neurons and enteroendocrine cells, which respond by releasing secondary mediators such as insulin-like growth factor-1, keratinocyte growth factor and nitric oxide. The trophic effect on the epithelium is therefore relayed, not direct.

What GLP-2 does in the gut

The overall effect of sustained GLP-2 signalling is a larger, better-perfused, less leaky intestinal surface. In animal and human studies the changes documented include:

Increased villus height and crypt depth, expanding the absorptive surface area.
Reduced enterocyte apoptosis, so cells persist longer on the villus.
Increased mesenteric and mucosal blood flow, supporting nutrient uptake.
Improved epithelial barrier function and reduced intestinal permeability.
Slowed gastric emptying and reduced gastric acid secretion, which extends contact time with the absorptive surface.

Why native GLP-2 is not a drug

Like GLP-1, native GLP-2 is cleaved at the second amino acid by dipeptidyl peptidase-4 (DPP-4), which inactivates it within minutes of release. That is appropriate for a local, meal-triggered signal, and useless for a medicine — a hormone that disappears in a few minutes cannot be dosed practically.

The engineering solution is the same one used for the incretin mimetics: substitute the amino acid that DPP-4 recognises. Teduglutide replaces the alanine at position 2 with glycine, which blocks the cleavage and extends the circulating half-life into a range that supports once-daily subcutaneous administration.

GLP-2 analogues in clinical use and development

Teduglutide is the established example. It is approved for short bowel syndrome — a condition in which surgical resection has left too little intestine to absorb adequate nutrition and fluid, leaving patients dependent on parenteral nutrition. By enlarging the remaining absorptive surface, it reduces how much intravenous support those patients require. That is a narrow, serious indication in a small population, and it is administered under specialist supervision.

Glepaglutide is a longer-acting GLP-2 analogue investigated for the same indication with the aim of less frequent administration. Development-stage compounds should be read as investigational until a regulator says otherwise; GLPWiki records phase and sponsor on each entry rather than anticipating approval.

The safety consequence of a growth signal

A drug whose mechanism is 'make intestinal tissue grow' inherits an obvious concern: unwanted growth. Approved labelling for teduglutide carries warnings regarding acceleration of neoplastic growth, and recommends colonoscopy before starting and periodically thereafter. Other labelled concerns include intestinal obstruction, biliary and pancreatic disease, and fluid overload as absorption improves. This is precisely the sort of risk profile that requires clinical supervision rather than self-experimentation.

GLP-2 versus GLP-1, side by side

The two peptides are worth contrasting directly, because the shared name causes more confusion than almost anything else in this field.

Origin: both from proglucagon in intestinal L-cells, co-secreted after meals.
Receptor: separate receptors with little cross-activation.
Primary target tissue: GLP-1 acts on pancreatic islets, stomach and brain; GLP-2 acts within the intestinal wall.
Effect on appetite and glucose: substantial for GLP-1, not a feature of GLP-2.
Effect on intestinal growth and absorption: not a feature of GLP-1, central to GLP-2.
Therapeutic use: GLP-1 analogues in type 2 diabetes and obesity; GLP-2 analogues in short bowel syndrome.

Common misconceptions

The first is that GLP-2 is a 'stronger' or 'next-generation' GLP-1 because of the higher number. The numbering reflects the order of fragments in the precursor, not potency or generation. By the same logic, the online nickname 'GLP-3' for retatrutide is not a continuation of any series — no GLP-3 hormone or receptor exists.

The second is that a GLP-2 analogue might help with weight. Its mechanism increases nutrient absorption, which points in the opposite direction from an obesity treatment, and it is neither indicated nor studied for that purpose.

The third is that gut-repair claims made for unrelated research peptides can be supported by GLP-2 data. They cannot. Evidence for one molecule acting on one receptor says nothing about another molecule acting elsewhere.

Frequently asked questions

Is GLP-2 the same as GLP-1?: No. They come from the same precursor protein and are released together, but they bind different receptors and do different jobs. GLP-1 affects insulin secretion, gastric emptying and appetite; GLP-2 grows and repairs the intestinal lining.
Does GLP-2 cause weight loss?: No. Its documented effect is to increase intestinal absorptive capacity, which is the opposite direction of travel from an obesity treatment. GLP-2 analogues are approved for short bowel syndrome, not weight management.
Is there a GLP-3?: No. There is no GLP-3 hormone or receptor. The term circulates online as a nickname for retatrutide, an investigational triple agonist of the GLP-1, GIP and glucagon receptors.
Why does GLP-2 need to be injected?: It is a peptide, so swallowing it exposes it to digestive proteases that would destroy it before absorption. Approved GLP-2 analogues are given subcutaneously.
What is teduglutide used for?: It is a DPP-4-resistant GLP-2 analogue approved for short bowel syndrome, where it increases absorption from the remaining intestine and reduces dependence on parenteral nutrition. It is used under specialist supervision with periodic colonoscopic monitoring.

SOURCES

01Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone GLP-2— Annual Review of Physiology (PubMed)
02Jeppesen PB et al. Teduglutide reduces need for parenteral support in short bowel syndrome— Gastroenterology (PubMed)
03GATTEX (teduglutide) prescribing information— U.S. Food and Drug Administration
04Sandvik J et al. GLP-2 receptor signalling and intestinal adaptation— Journal of Physiology / PubMed
05Naimi RM et al. Glepaglutide in short bowel syndrome: phase 2 trial— The Lancet Gastroenterology & Hepatology (PubMed)

EDUCATIONAL REFERENCE ONLY · Not medical advice. Nothing here diagnoses, treats, cures or prevents any disease, and nothing here is a dosing recommendation. Consult a licensed clinician before any treatment decision.